Elevation Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Elevation Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$28.8K	Hold	55	–	–	0.01%	557
2026 Q2	$27.3K	Buy	55 +28	+104%	+$12.4K	0.01%	485
2026 Q1	$12.1K	Buy	27 +1	+4%	+$466	﹤0.01%	472
2025 Q4	$11.8K	Buy	26 +13	+100%	+$5.6K	﹤0.01%	458
2025 Q3	$5.09K	Buy	+13	New	+$5.43K	﹤0.01%	478
2025 Q1	–	Sell	-94	Closed	-$37.9K	–	515
2024 Q4	$37.9K	Hold	94	–	–	0.02%	258
2024 Q3	$43.7K	Hold	94	–	–	0.02%	232
2024 Q2	$44.1K	Hold	94	–	–	0.02%	225
2024 Q1	$39.3K	Buy	+94	New	+$39.7K	0.02%	237

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Elevation Wealth Partners's VRTX Position: Q3 2026 in Review

Elevation Wealth Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 55 shares worth $28.8K. The position accounts for 0.01% of the portfolio, ranked #557.

Elevation Wealth Partners first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $44.1K in Q2 2024. 870 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Elevation Wealth Partners held 55 shares of Vertex Pharmaceuticals worth $28.8K as of Q3 2026.
Elevation Wealth Partners left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
Vertex Pharmaceuticals made up 0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #557 holding.
Elevation Wealth Partners first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Elevation Wealth Partners's Vertex Pharmaceuticals position peaked at $44.1K in Q2 2024.
870 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.